Condition Directory

Breast Cancer clinical trials

Directory of U.S. ClinicalTrials.gov public records for Breast Cancer. Browse Breast Cancer recruiting trials, filter by phase, sponsor, location, or intervention, and open the official ClinicalTrials.gov study record for each result.

By Clinical Trials Finder Guidance last reviewed June 10, 2026 Data synced October 21, 2026 Report an issue

ClinicalTrials.gov public records Last synced Oct 21, 2026, 7:00 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

679

Shown on this page

Current sort

How Breast Cancer studies are organized in the registry

Breast cancer listings are usually subtype-specific: receptor status appears directly in titles and condition fields, so subtype terms narrow results far better than stage words alone. Many studies also restrict to either early-stage or metastatic settings, which is visible in the title or eligibility section of the official record.

Terms that often appear in related listings

triple-negative HER2-positive hormone receptor-positive metastatic breast cancer

These describe how studies tend to be titled and grouped on ClinicalTrials.gov — they are search vocabulary, not medical guidance.

Showing 577–588 of 679 matching trials for Breast Cancer.

Live ClinicalTrials.gov results.

Active filters: "hormone receptor-positive" Clear condition filters

Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Open in full search

Conditions: Breast Cancer
Interventions: Not listed
Lead sponsor: Agendia; Industry
Eligibility: 18 Years and older
Enrollment: 481 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 17
States / cities: Palm Springs, California • Miami, Florida • Tampa, Florida + 13 more

Conditions: Metastatic Breast Cancer
Interventions: Eribulin, Trastuzumab; Drug
Lead sponsor: SCRI Development Innovations, LLC; Other
Eligibility: 18 Years and older · Female only
Enrollment: 127 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 18
States / cities: Fort Myers, Florida • Lakeland, Florida • Orlando, Florida + 12 more

Conditions: Metastatic Breast Cancer
Interventions: IMC-A12 (cixutumumab), tamoxifen, Anastrozole, Letrozole, Exemestane, Fulvestrant; Biological · Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 93 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2015
U.S. locations: 9
States / cities: Scottsdale, Arizona • Chicago, Illinois • Westwood, Kansas + 6 more

Conditions: Metastatic Breast Cancer
Interventions: Fulvestrant, Everolimus, Placebo; Drug
Lead sponsor: PrECOG, LLC.; Other
Eligibility: 18 Years and older
Enrollment: 131 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 25
States / cities: Greenbrae, California • Stanford, California • Rockford, Illinois + 21 more

Conditions: Estrogen Receptor Positive, HER2/Neu Negative, Male Breast Carcinoma, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
Interventions: Fluorothymidine F-18, Positron Emission Tomography, Laboratory Biomarker Analysis, Run-in (short pre-surgery course) of endocrine-targeted therapy; Drug · Procedure · Other
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Estrogen Receptor Positive, HER2/Neu Negative, Recurrent Breast Carcinoma, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
Interventions: Akt Inhibitor MK2206, Anastrozole, Goserelin Acetate, Laboratory Biomarker Analysis, Neoadjuvant Therapy, Pharmacological Study, Therapeutic Conventional Surgery; Drug · Other · Procedure
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 8
States / cities: Scottsdale, Arizona • Chicago, Illinois • Iowa City, Iowa + 5 more

Conditions: Breast Cancer
Interventions: letrozole, MRI, conventional surgery; Drug · Procedure
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older · Female only
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 32
States / cities: Los Angeles, California • Oakland, California • San Francisco, California + 22 more

Conditions: Estrogen Receptor-negative Breast Cancer, Estrogen Receptor-positive Breast Cancer, HER2-positive Breast Cancer, Progesterone Receptor-negative Breast Cancer, Progesterone Receptor-positive Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer
Interventions: doxorubicin hydrochloride, cyclophosphamide, paclitaxel, filgrastim, capecitabine, methotrexate, vinorelbine tartrate, needle biopsy, therapeutic conventional surgery, immunohistochemistry staining method, trastuzumab, tamoxifen citrate, letrozole, laboratory biomarker analysis; Drug · Biological · Procedure + 1 more
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older · Female only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2011
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Breast Cancer
Interventions: fulvestrant, sorafenib tosylate; Drug
Lead sponsor: OHSU Knight Cancer Institute; Other
Eligibility: 18 Years to 120 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Breast Cancer
Interventions: Dovitinib, Aromatase Inhibitors; Drug
Lead sponsor: Georgetown University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Hormone-receptor Positive Breast Cancer
Interventions: exemestane and pazopanib; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Breast Cancer
Interventions: naltrexone, PET scan; Drug · Procedure
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: 18 Years and older · Female only
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2013
U.S. locations: 1
States / cities: Minneapolis, Minnesota

About this Breast Cancer clinical trials directory page

What this page lists: U.S. ClinicalTrials.gov public records that list Breast Cancer as a study condition, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
How to narrow results: Use the filters above to scope by intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Breast Cancer.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Breast Cancer clinical trials

How Breast Cancer studies are organized in the registry

Filter and sort this condition

Live official records

Measuring the Impact of MammaPrint on Adjuvant and Neoadjuvant Treatment in Breast Cancer Patients: A Prospective Registry

Trial of Eribulin in Patients Who Do Not Achieve Pathologic Complete Response (pCR) Following Neoadjuvant Chemotherapy

A Study for Safety and Effectiveness of IMC-A12 by Itself or Combined With Antiestrogens to Treat Breast Cancer

Study of Fulvestrant +/- Everolimus in Post-Menopausal, Hormone-Receptor + Metastatic Breast Ca Resistant to AI

FLT PET in Measuring Treatment Response in Patients With Newly Diagnosed Estrogen Receptor-Positive, HER2-Negative Stage I-III Breast Cancer

Akt Inhibitor MK-2206 and Anastrozole With or Without Goserelin Acetate in Treating Patients With Stage II-III Breast Cancer

Letrozole in Treating Postmenopausal Women With Ductal Carcinoma in Situ

Combination Chemotherapy and Filgrastim Before Surgery in Treating Patients With HER2-Positive Breast Cancer That Can Be Removed By Surgery

Sorafenib and Fulvestrant in Treating Patients With Locally Advanced or Metastatic Breast Cancer That Did Not Respond to Aromatase Inhibitor Therapy

Dovitinib Plus an Aromatase Inhibitor for Metastatic Breast Cancer

Phase II Study Evaluating Exemestane Alone Or In Combination With Pazopanib In Postmenopausal Women With Hormone Receptor Positive Breast Cancer

Phase II of Naltrexone in Hormone-Refractory Metastatic Breast Cancer

About this Breast Cancer clinical trials directory page